Lilly to acquire Atai Beckley to advance therapies for treatment-resistant depression and other mental health conditions through a strategic psychedelic medicine deal

Lilly is acquiring Atai Beckley to expand its pipeline for treatment-resistant depression and other mental health conditions, signaling deeper pharmaceutical investment in psychedelic-inspired and novel neuropsychiatric therapies. The deal centers on advancing drug development for patients who have not responded to existing treatments. It places a major pharmaceutical company alongside a biotech focused on next-generation mental health therapeutics, with the transaction framed around research, clinical development, and eventual commercialization. The acquisition matters because it strengthens mainstream industry participation in a field long driven by smaller biotech firms and research groups. It also reflects growing confidence that new approaches for severe depression and related disorders could become an important part of future psychiatric care.